- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05053282
Long-life Endurance Exercise and Healthy Aging (CAA)
Active Aging: Effect of Life-long Endurance Exercises on the Circadian Regulation of Physiological Processes and Their Maintenance in Aging
The project aims to explore the mechanisms by which lifelong exercise can promote healthy aging and slow down the negative impact of aging on the muscular system, immunity and the circadian system. The main goal of the project is to investigate the effect of lifelong endurance exercise on physical fitness, body composition, bone density and selected hormonal, biochemical, histological and molecular indicators of metabolic health and circadian clock function based on blood, immune cell and skeletal muscle tissue analyses in volunteers differentiated by age and weekly volume of physical activity.
It is hypothesized that lifelong endurance exercise may have beneficial effects on the circadian system stability and many, but not all health outcomes. Osteopenia/osteoporosis and low-grade malnutrition may be more prevalent in the group of endurance-trained senior runners.
In order to achieve the above research aims, sixty male subjects in total will be recruited according to inclusion and exclusion criteria. Four groups of subjects will differ according to their age and physical activity levels:
- a group of endurance-trained seniors (age range 65 - 75 year old, n=15) ● a group of sedentary seniors (age range 65 - 75 year old, n=15)
- a group of well endurance-trained young men (age range 20 - 30 year old, n=15) ● a group of sedentary young men (age range 20 - 30 year old, n=15).
Subjects must meet the following inclusion criteria:
- for athletes' groups: defined as more than 150 minutes of running activity per week; for young athletes at least 3 years and for master athletes at least 15 years history of running.
- for groups less active than recommended: no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week.
The standard inclusion criterion for every group will be body mass index (range 18.5-30 kg/m2).
No experimental study has been published on the potential of life-long exercise to attenuate the aging-induced disorganization of the circadian system and thus to promote healthy aging. In this aspect, the proposed study is original and up-to-date. Moreover, also other aspects of the study, e.g. exercise and inflammaging or the risks (besides the benefits) of the long-life endurance training on bone tissue etc. have been studied only scarcely. Therefore, more scientific information is needed before it can be safely prescribed to the aging population
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Milan Sedliak, assoc. prof.
- Phone Number: +421907247021
- Email: milan.sedliak@uniba.sk
Study Locations
-
-
-
Bratislava, Slovakia, 814 99
- Recruiting
- Comenius University in Bratislava, Faculty of physical education and sport Bratislava, Slovakia
-
Contact:
- Milan Sedliak, assoc. prof.
- Phone Number: +421907247021
- Email: milan.sedliak@uniba.sk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
for athletes' groups (master - 65 - 75 years old, and young athletes - 20 - 30 years old)
- more than 150 minutes of running activity which is by ACSM considered as vigorous intensity of endurance running for young athletes at least 3 years and for master athletes at least 15 years
- body mass index (BMI index) - range 18.5-30 kg/m2
for groups less active than recommended (sedentary young and elderly)
- no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week
- body mass index (BMI index) - range 18.5-30 kg/m2
Exclusion Criteria
- recent or current infection
- malignant disease
- uncontrolled hypertension (higher than 160 / 95mmHG)
- congestive heart failure (NYHA grade III and IV)
- unstable angina pectoris
- recent myocardial infarction (during the last 6 months)
- severe cardiac arrhythmia (anamnestic)
- chronic obstructive pulmonary disease
- presence of severe pulmonary, pleural or pericardial disease
- severe asthma
- recent sudden stroke (during the last 6 months)
- epilepsy
- insulin-dependent diabetes mellitus
- unstable bone lesions with a high risk of fractures
- other chronic diseases, at the discretion of the responsible doctor
- states of mental incompetence (severe anxiety and depression, dementia, alcoholism , or other dependencies, mental retardation)
- conditions complicating regular physical activity (uncontrollable pain, severe arthritis, planned knee / hip endoprosthesis, pathological fractures (last 6 months), amputation, use of walker, wheelchair
- pharmacological interference (e.g., steroids, nonsteroidal anti-inflammatory agents, immunosuppressive and antineoplastic drugs, beta blockers, statins)
- the use of performance-enhancing drugs in the past and during the study period
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
master endurance athletes
men aged 65 to 75 with more than 150 minutes of running activity per week at least 15 years history of running
|
regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
|
|
elderly sedentary
men aged 65 to 75 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
|
|
|
young endurance athletes
men aged 20 to 30 with more than 150 minutes of running activity per week at least 3 years history of running
|
regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
|
|
young sedentary
men aged 20 to 30 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
maximal oxygen consumption
Time Frame: cross-sectional, one-point assessment over 1 day
|
peak oxygen consumption normalised to body mass (mL/kg/min), measured through a graded cycling ergometry
|
cross-sectional, one-point assessment over 1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
body composition
Time Frame: cross-sectional, one-point assessment over 1 day
|
DXA method - fat mass (grams), lean mass (grams) and total mass (grams)
|
cross-sectional, one-point assessment over 1 day
|
|
bone mineral content
Time Frame: cross-sectional, one-point assessment over 1 day
|
DXA method - BMC (grams)
|
cross-sectional, one-point assessment over 1 day
|
|
bone mineral density
Time Frame: cross-sectional, one-point assessment over 1 day
|
DXA method - BMD (g/cm2)
|
cross-sectional, one-point assessment over 1 day
|
|
maximum isometric muscle strength
Time Frame: cross-sectional, one-point assessment over 1 day
|
maximum voluntary contraction (Nm) of both isometric extension and flexion on knee dynamometer
|
cross-sectional, one-point assessment over 1 day
|
|
maximum isometric muscle torque development
Time Frame: cross-sectional, one-point assessment over 1 day
|
rate of torque development (Nm/s) of both isometric extension and flexion on knee dynamometer
|
cross-sectional, one-point assessment over 1 day
|
|
Immunohistochemical analyses - skeletal muscle cell morphometry
Time Frame: cross-sectional, one-point assessment over 1 day
|
cross-sectional area (um2) of myosin heavy chain I (BA-D5) positive fibers
|
cross-sectional, one-point assessment over 1 day
|
|
Immunohistochemical analyses - skeletal muscle tissue morphology
Time Frame: cross-sectional, one-point assessment over 1 day
|
number of myonuclei, satellite cells, capillaries - counted per each fiber type nuclear number per fiber
|
cross-sectional, one-point assessment over 1 day
|
|
circadian system phase
Time Frame: cross-sectional, two-point assessment at morning and afternoon over 1 day
|
CD14-positive monocytes (mRNA levels of selected clock and clock-controlled genes /alternatively microarray analysis in sub-sample of subjects from each group) blood count
|
cross-sectional, two-point assessment at morning and afternoon over 1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
skeletal muscle tissue - (PCR) RNA expression
Time Frame: cross-sectional, one-point assessment over 1 day
|
Target genes for inflammatory markers
|
cross-sectional, one-point assessment over 1 day
|
|
biochemical biomarkers of nitrogen compounds
Time Frame: cross-sectional, one-point assessment over 1 day
|
creatinine (umol/L), total bilirubin (umol/L),uric acid(umol/L)
|
cross-sectional, one-point assessment over 1 day
|
|
biochemical biomarkers of lipid and carbohydrate metabolism
Time Frame: cross-sectional, one-point assessment over 1 day
|
serum glucose (mmol/L), total cholesterol urea (mmol/L), low-density lipoprotein cholesterol urea (mmol/L), high-density lipoprotein cholesterol urea (mmol/L), triacylglycerols (mmol/L)
|
cross-sectional, one-point assessment over 1 day
|
|
biochemical malnutrition biomarkers
Time Frame: cross-sectional, one-point assessment over 1 day
|
transthyretin, retinol binding protein(μg/mL)
|
cross-sectional, one-point assessment over 1 day
|
|
biochemical liver function biomarkers
Time Frame: cross-sectional, one-point assessment over 1 day
|
aspartate aminotransferase (ukat/L), alanine aminotransferase (ukat/L), γ-glutamyltransferase (ukat/L)
|
cross-sectional, one-point assessment over 1 day
|
|
dietary macronutirents intake tracking
Time Frame: cross-sectional, one-point assessment over seven consecutive days
|
Macronutrients (carbohydrate, fat, and protein in grams) data will be retrieved from each participant's diary and expressed as a daily average for total intakes.
|
cross-sectional, one-point assessment over seven consecutive days
|
|
dietary energy intake tracking
Time Frame: cross-sectional, one-point assessment over seven consecutive days
|
Energy (kilocalorie) data will be retrieved from each participant's diary and expressed as a daily average for total and relative intakes.
|
cross-sectional, one-point assessment over seven consecutive days
|
|
physical activity monitoring
Time Frame: cross-sectional, one-point assessment over seven consecutive days
|
ActivPAL device - static and dynamic acceleration to distinguish body posture as sitting/lying, standing, and stepping and estimate energy expenditure expressed as metabolic equivalents - MET
|
cross-sectional, one-point assessment over seven consecutive days
|
|
chronotype
Time Frame: cross-sectional, one-point assessment over 1 day
|
score in The Munich ChronoType Questionnaire (MCTQ), total scores can range from 16 to 86, with the lowest values representing extreme-late chronotypes.
|
cross-sectional, one-point assessment over 1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ján Cvečka, PhD., Comenius University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 305041X157
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Florida Institute for Human and Machine CognitionNot yet recruitingAging | Healthy Aging | Aging WellUnited States
-
University of CopenhagenRecruitingAging | Healthy Aging | Aging FrailtyDenmark
-
Radboud University Medical CenterTerminated
-
Northwestern UniversityPotocsnak Human Longevity LabRecruitingAging | Aging Well | Aging, Biological | Aging, HealthyUnited States
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
Arizona State UniversityActive, not recruiting
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Centre Hospitalier Universitaire de NiceNot yet recruitingAging | Aging, HealthyFrance
Clinical Trials on endurance running exercise
-
Maastricht University Medical CenterCompletedMuscle Protein SynthesisNetherlands
-
St. Joseph's Healthcare HamiltonCompletedStress | Sleep | Mood | Attention | Memory | LearningCanada
-
University of MichiganCompletedDepression | Anxiety | Bipolar Disorder | Major Depressive DisorderUnited States
-
University Hospital of SplitUniversity of MarylandCompletedEndothelial Dysfunction | Decompression Sickness | Neutrophil Activation | Venous Gas EmboliUnited States, Croatia
-
Middle East Technical UniversityCompletedOsteoarthritis | Degenerative Lesion of Articular Cartilage of Knee | Articular Cartilage Disorder of KneeTurkey
-
Nordic Bioscience A/SUniversity of Copenhagen; NBCD A/SCompleted
-
University of Illinois at Urbana-ChampaignNational Heart, Lung, and Blood Institute (NHLBI)CompletedVascular Health | Autonomic FunctionUnited States
-
University of TorontoCompleted
-
Riphah International UniversityCompleted
-
Norwegian University of Science and TechnologyLHL-Klinikkene, Røros; LHL-Klinikkene, FeiringWithdrawnVentricular Dysfunction, Left | Heart Failure, DiastolicNorway